By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


MediciNova, Inc. 

4350 La Jolla Village Drive, Suite 950

San Diego  California  92122  U.S.A.
Phone: 858-373-1500 Fax: 858-373-7000



Company News
MediciNova, Inc. To Present At The Ladenburg Thalmann 2015 Healthcare Conference 9/24/2015 9:50:38 AM
FDA Grants Fast Track Designation For MediciNova, Inc.'s MN-001 (Tipelukast) For The Treatment Of Idiopathic Pulmonary Fibrosis 9/10/2015 7:22:15 AM
MediciNova, Inc. Announces First Advanced ALS Patient Using Non-Invasive Ventilation Support Enrolled In Phase II Clinical Trial Of MN-166 (Ibudilast) 9/3/2015 7:14:56 AM
MediciNova, Inc. Announces Closing Of Underwritten Public Offering Of Common Stock 8/25/2015 7:06:29 AM
MediciNova, Inc. Announces Pricing Of Underwritten Public Offering Of Common Stock 8/19/2015 7:14:16 AM
MediciNova, Inc. Announces Proposed Underwritten Public Offering Of Common Stock 8/19/2015 7:13:22 AM
MediciNova, Inc. Release: MN-166 (Ibudilast) ALS Abstract Accepted For Presentation At The 26th International Symposium On ALS/MND In Orlando, FL: Interim Safety And Clinical Outcomes To Be Presented 7/28/2015 7:17:06 AM
MediciNova, Inc. Announces FDA Approval Of The Second Phase II Protocol For MN-001 In NASH Which Targets NASH Patients With Hypertriglyceridemia 7/27/2015 7:11:15 AM
MediciNova, Inc. Announces Update On Development Plans For MN-001 In IPF 7/21/2015 7:22:13 AM
MediciNova, Inc. Announces The Completion Of Enrollment In Clinical Trial Of MN-166 (Ibudilast) In Alcohol Dependence 7/1/2015 6:58:29 AM